Overcome cancer drug resistance by targeting epigenetic modifications of centrosome

Zanhui Jia, Xinggang Wang, Hong ZhangCancer 2019 · DOI

Abstract

The centrosome is an organelle that serves as the microtubule- and actin-organizing center of human cells. Although the centrosome is small of size, it is great important on cellular function that regulates cytoskeletal organization and governs precise spindle orientation/positioning ensuring equal distribution of cellular components in cell division. Epigenetic modifications to centrosome proteins can lead to centrosome aberrations, such as disorganized spindles and centrosome amplification causing aneuploidy and genomic instability. Epigenetic disturbances are associated not only with carcinogenesis and cancer progression, but also with drug resistance to chemotherapy. In this review, we discuss mechanisms of epigenetic alteration during the centrosome biogenesis in cancer. We provide an update on the current status of clinical trials that aim to target epigenetic modifications in centrosome aberrations and to thwart drug resistance.

Introduction: The Centrosome as a Cellular Command Center

In healthy human cells, the centrosome acts as the primary structural "command center," organizing the microtubules and actin filaments necessary for cellular architecture and division. During mitosis, two centrosomes establish the poles of the mitotic spindle, ensuring that genetic material is partitioned equally between daughter cells. However, cancer cells frequently exhibit centrosome amplification (CA)—the presence of three or more centrosomes. This aberration drives genomic instability and aneuploidy, providing a fertile ground for tumor evolution and the development of drug resistance.

While genetic mutations are often cited as the cause of centrosome dysfunction, emerging research highlights the critical role of epigenetic modifications. These chemical "volume knobs," such as phosphorylation, acetylation, and ubiquitination, regulate the expression and activity of centrosome proteins without altering the underlying DNA sequence. This review explores how these epigenetic tweaks allow cancer cells to evade chemotherapy and identifies new therapeutic strategies to reverse these effects.

Mechanisms of Centrosome-Driven Resistance

Research indicates that centrosome-related drug resistance is not a single-track process but involves several complex mechanisms:

1. Gene Dosage and Protein Overabundance

The duplication of centrosomes is tightly controlled by master regulators like PLK4 and Aurora A. Epigenetic disturbances can lead to an overabundance of these proteins, triggering uncontrolled centrosome duplication. For instance, the acetylation of PLK4 by KAT2A/B normally prevents over-duplication; when this epigenetic control fails, the resulting centrosome amplification leads to the "shuffled" DNA characteristic of aggressive, treatment-resistant tumors.

2. Mitotic Slippage

Many chemotherapies, such as taxanes (e.g., paclitaxel), work by arresting cells during mitosis to trigger cell death. However, some cancer cells utilize a survival mechanism known as "mitotic slippage." Centrosome proteins like CEP55 can help a cell bypass the death signal during a failed division. Instead of dying, the cell "slips" out of mitosis and survives as a polyploid cell, which is often significantly more resistant to subsequent rounds of treatment.

3. Activation of Drug Transporters

One of the most striking discoveries in recent years is the role of centrosome proteins in active drug efflux. The protein NEK2, which primarily regulates centrosome separation, has been identified as a "double agent." Beyond its structural role, NEK2 can directly upregulate ABC transporters—cellular pumps that actively eject chemotherapy drugs like cisplatin and doxorubicin from the cell before they can take effect.

Clinical Progress and Therapeutic Targets

Translating these mechanistic insights into the clinic is already underway. By targeting the specific chemical "tags" and proteins involved in centrosome biogenesis, researchers hope to sensitize resistant tumors to standard therapies.

  • PLK1 Inhibition: In clinical trials for Acute Myeloid Leukemia (AML), combining the PLK1 inhibitor BI 6727 with the standard chemotherapy drug cytarabine showed significant promise. The combination increased the total remission rate from 13% to 31%, demonstrating the potential of targeting centrosome regulators.
  • PLK4 Targeting: CFI-400945, a first-in-class selective inhibitor of PLK4, is currently undergoing clinical trials for advanced solid tumors. By inhibiting the master regulator of centrosome duplication, this drug aims to halt the cycle of genomic instability.
  • NEK2 as a Biomarker: High expression levels of NEK2 have been consistently linked to multi-drug resistance in myeloma, breast, and liver cancers, suggesting its potential as a biomarker to identify patients who may require more aggressive or targeted intervention.

Future Perspectives

While the identification of these regulatory pathways marks a significant step forward, the complexity of centrosome signaling—including intricate feedback loops and protein trafficking between the centrosome and the nucleus—remains a challenge.

Future research must focus on combination therapies, potentially pairing epigenetic centrosome inhibitors with immunotherapy to overcome the adaptive mechanisms of cancer. Furthermore, utilizing centrosome amplification as a personalized biomarker could allow clinicians to tailor treatments to the specific molecular profile of an individual's tumor, finally breaking the cycle of drug resistance.

Summary updated

Abstract

The centrosome is an organelle that serves as the microtubule- and actin-organizing center of human cells. Although the centrosome is small of size, it is great important on cellular function that regulates cytoskeletal organization and governs precise spindle orientation/positioning ensuring equal distribution of cellular components in cell division. Epigenetic modifications to centrosome proteins can lead to centrosome aberrations, such as disorganized spindles and centrosome amplification causing aneuploidy and genomic instability. Epigenetic disturbances are associated not only with carcinogenesis and cancer progression, but also with drug resistance to chemotherapy. In this review, we discuss mechanisms of epigenetic alteration during the centrosome biogenesis in cancer. We provide an update on the current status of clinical trials that aim to target epigenetic modifications in centrosome aberrations and to thwart drug resistance.
BibTeX
@inproceedings{jia2019overcome,
  author = {Zanhui Jia and Xinggang Wang and Hong Zhang},
  title = {{Overcome cancer drug resistance by targeting epigenetic modifications of centrosome}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.20517/cdr.2018.010},
}
Figure